Your browser doesn't support javascript.
loading
Nonarteritic anterior ischemic optic neuropathy associated with interferon and ribavirin in a patient with hepatitis C.
Sharif, Walid; Sheikh, Khayam; De Silva, Ian; Elsherbiny, Samer.
Afiliación
  • Sharif W; Department of Ophthalmology, Birmingham & Midland Eye Centre, City Hospital NHS Trust, Birmingham B18 7QH, UK.
  • Sheikh K; Department of Ophthalmology, Birmingham & Midland Eye Centre, City Hospital NHS Trust, Birmingham B18 7QH, UK.
  • De Silva I; Department of Ophthalmology, Birmingham & Midland Eye Centre, City Hospital NHS Trust, Birmingham B18 7QH, UK.
  • Elsherbiny S; Department of Ophthalmology, Birmingham & Midland Eye Centre, City Hospital NHS Trust, Birmingham B18 7QH, UK.
Am J Ophthalmol Case Rep ; 5: 52-55, 2017 Apr.
Article en En | MEDLINE | ID: mdl-29503948
ABSTRACT

PURPOSE:

To report a case of a temporal artery biopsy negative anterior ischemic optic neuropathy associated with a recently completed course of pegylated interferon 2 α with ribavirin for chronic hepatitis C. OBSERVATIONS Despite the early presentation with symptoms and prompt treatment with systemic intravenous steroids the patient experienced deterioration of their optic neuropathy over the following few days. Although nonarteritic anterior ischemic optic neuropathy is a common disorder with known risk factors, the timing of onset of symptoms in our patient was suggestive of a possible etiology related to treatment with ribavirin and interferon 2 α, as found in the previously reported cases. CONCLUSIONS AND IMPORTANCE There have been a few reported cases of the association between the use of interferon/ribavirin for treatment of chronic hepatitis with nonarteritic anterior ischemic optic neuropathy. In these cases stopping the drug caused some improvement of symptoms or halting the progression of optic neuropathy. Having reviewed the literature on previous cases, we postulate that there may be a dose related reaction to explain the delay and deterioration of vision in some cases despite stopping the drugs. We also advise that any person who is started on this treatment for chronic hepatitis are appropriately counselled as to the potential optic nerve side effect of the drug, based on the evidence reported in the literature.
Palabras clave